Abstract:The fifth edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO‐HAEM5) is the product of an evidence‐based evolution of the revised fourth edition with wide multidisciplinary consultation. Nonetheless, while every classification incorporates scientific advances and aims to improve upon the prior version, medical knowledge remains incomplete and individual neoplasms may not be easily subclassified in a given scheme. Thus, optimal classification requires ongoing study, and there are certain aspects of some entities and subtypes that require further refinements. In this review, we highlight a selection of these challenging areas to prompt more research investigations. These include (1) a 'placeholder term' of splenic B‐cell lymphoma/leukaemia with prominent nucleoli (SBLPN) to accommodate many of the splenic lymphomas previously classified as hairy cell leukaemia variant and B‐prolymphocytic leukaemia, a clear new start to define their pathobiology; (2) how best to classify BCL2 rearrangement negative follicular lymphoma including those with BCL6 rearrangement, integrating the emerging new knowledge on various germinal centre B‐cell subsets; (3) what is the spectrum of non‐IG gene partners of MYC translocation in diffuse large B‐cell lymphoma/high‐grade B‐cell lymphoma and how they impact MYC expression and clinical outcome; how best to investigate this in a routine clinical setting; and (4) how best to define high‐grade B‐cell lymphoma not otherwise specified and high‐grade B‐cell lymphoma with 11q aberrations to distinguish them from their mimics and characterise their molecular pathogenetic mechanism. Addressing these questions would provide more robust evidence to better define these entities/subtypes, improve their diagnosis and/or prognostic stratification, leading to better patient care. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Review of the 2016 WHO Classification of Lymphoid Neoplasms

[New WHO Classification of Lymphoid Neoplasms: Understanding and Consideration].

Lymphoma classification update: B-cell non-Hodgkin lymphomas

Clinical Impact of the 2016 Update to the WHO Lymphoma Classification

The World Health Organization Classification of Lymphoid Neoplasms

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion

Updates of Peripheral T Cell Lymphomas Based on the 2017 WHO Classification

The fifth edition of the WHO classification of mature B‐cell neoplasms: open questions for research

Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management

A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas

The 5th edition of the World Health Organization Classification of mature lymphoid and stromal tumors – an overview and update

New classifications of B-cell neoplasms: a comparison of 5th WHO and International Consensus classifications

Classification of B-Cell Lymphomas and Immunodeficiency-Related Lymphoproliferations: What’s New?

High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification

Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissues: B-cell Neoplasms

The fifth edition of the WHO-Classification - what is new for cutaneous lymphomas?

Epidemiology and Pathology of T- and NK-Cell Lymphomas

What is new in the 5th edition of the World Health Organization classification of mature B and T/NK cell tumors and stromal neoplasms?

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms—Updated Classification and New Concepts

Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues